Diagnosis
Spirometry
Control Assessment
Maintenance Treatment
Exacerbations
100

This test is the best in-clinic study to support a diagnosis of asthma.

Spirometry

100

Medication commonly used to assess obstruction reversibility

Short acting beta agonist

100

Using albuterol more than this many days per week suggests poor control.

More than 2 days per week

100

This medication is for rescue, not control.

 SABA (albuterol)

100

Inability to speak full sentences and accessory muscle use = this severity.

Severe exacerbation

200

Asthma requires BOTH typical symptoms and this objective finding.

 Evidence of variable airflow limitation/obstruction

200

This change after bronchodilator confirms reversibility.

FEV1 increase ≥12%

200

Number of nocturnal awakenings indicating poor control

>/= 1 monthly
200

First-line controller medication class.

Inhaled corticosteroids

200

First-line acute therapy.

Inhaled SABA

300

This spirometric ratio is used to identify obstruction.

FEV1/FVC

300

This parameter reflects airway obstruction

FEV1/FVC

300

This is the best objective tool to follow asthma control.

Spirometry

300

Check this before stepping up therapy

Technique/adherence

300

Should be added early in moderate–severe exacerbations.

Systemic corticosteroids

400

DAILY DOUBLE – Normal spirometry but high suspicion: this test can confirm asthma.

Bronchoprovocation testing (methacholine or exercise)

400

This value is used to diagnose obstructive airway disease in children.

FEV1/FVC ratio < LLN (80-85%)

400

Number of exacerbations requiring systemic steroids indicating poor control

>1 in last 12 months

400

Alternative or add-on controller class.

Leukotriene receptor antagonists

400

Life threatening sign/possible impending intubation

Silent chest/Minimal or absent air movement with breathing

500

What spirometry finding distinguishes Asthma from COPD?

Reversible obstruction

500

Methacholine or exercise challenge test positive result

>20% decrease in FEV1 from baseline

500
Treatment duration to assess step down therapy

at least 3 months

500

Chronic daily use should be avoided due to toxicity.

Systemic (oral) steroids

500

Add on IV therapy to help with bronchodilation.

IV Magnesium sulfate

M
e
n
u